Therefore, regardless of the mutation status of EGFR or K-Ras in NSCLC cells, exposure to gemcitabine followed by sorafenib was shown to exert synergistic effects, whereas the effect of the reversed sequence is antagonistic. Here, EGFR is linked to non-small cell lung carcinoma.